ICCC (ImmuCell) Ending Cash Position: $8.86 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ICCC ImmuCell Corp ICCC
51 GF Score
Price $10.15
GF Value $6.91
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is ImmuCell Ending Cash Position?

ImmuCell ICCC -0.39% 51 Ending Cash Position is $8.86 Mil as of Jun. 2026. GuruFocus rates ICCC with a GF Score™ of 51/100 and a GF Value™ of $6.91 (Significantly Overvalued). The stock has 5 warning signs investors should review.

ImmuCell's Ending Cash Position for the quarter that ended in Jun. 2026 was $8.86 Mil.

ImmuCell's quarterly Ending Cash Position increased from Dec. 2025 ($3.81 Mil) to Mar. 2026 ($6.81 Mil) and increased from Mar. 2026 ($6.81 Mil) to Jun. 2026 ($8.86 Mil).

ImmuCell's annual Ending Cash Position increased from Dec. 2023 ($0.98 Mil) to Dec. 2024 ($3.76 Mil) and increased from Dec. 2024 ($3.76 Mil) to Dec. 2025 ($3.81 Mil).

ImmuCell Ending Cash Position Related Terms

ImmuCell Ending Cash Position Historical Data

* Premium members only.

The historical data trend for ImmuCell's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ImmuCell Ending Cash Position Chart

ImmuCell Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.19 5.79 0.98 3.76 3.81

ImmuCell Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 3.89 3.81 6.81 8.86
ICCC
51GF Score
ImmuCell Corp ICCC
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ImmuCell Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

ImmuCell's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=3.758+0.049
=3.81

ImmuCell's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=6.813+2.047
=8.86

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $8.86 Mil mean?
ImmuCell (ICCC) has a Ending Cash Position of $8.86 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on ImmuCell and its competitors.
Is ImmuCell's Ending Cash Position too high?
ImmuCell's current Ending Cash Position is $8.86 Mil. Overall, ImmuCell has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ImmuCell's Ending Cash Position compare to COYA and ENTX?
ImmuCell's Ending Cash Position of $8.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on ImmuCell and its competitors. ImmuCell's current Ending Cash Position is $8.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuCell stock overvalued right now?
Based on GuruFocus' analysis, ImmuCell (ICCC) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.91, compared to a current price of $10.15 — trading 46.9% above its estimated fair value. The current Ending Cash Position is $8.86 Mil. ImmuCell's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For ImmuCell (ICCC), the current Ending Cash Position is $8.86 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ImmuCell (ICCC) Overvalued in 2026?

Based on GuruFocus' analysis, ImmuCell stock appears to be overvalued. The current stock price of $10.15 is trading 46.9% above its estimated GF Value™ of $6.91. GuruFocus considers ImmuCell to be Significantly Overvalued.

Key valuation signals for ICCC:

  • Ending Cash Position: $8.86 Mil
  • GF Value™: $6.91 vs. price of $10.15 (46.9% above fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the ICCC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ImmuCell Business Description

Other Exchanges IUL:Germany
Address 56 Evergreen Drive, Portland, ME, USA, 04103
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
51GF Score

Get the complete analysis for ICCC

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.15
Price
$6.91
GF Value